Clinical trial
Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube…
NCT00003624 · Gynecologic Oncology Group, Other · Terminated
Key facts
| NCT number | NCT00003624 |
|---|---|
| Title | Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer |
| Official title | A Limited Access Trial Using Amifostine for Protection Against Cisplatin and 3-Hour Paclitaxel-Induced Neurotoxicity |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Neurotoxicity, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Sarcoma |
| Intervention type | Drug |
| Interventions | amifostine trihydrate, cisplatin, paclitaxel |
| Start date | Dec 1, 1998 |
| Primary completion | Jan 1, 2004 |
| First posted | Jun 16, 2004 |
| Last update posted | Apr 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: